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Pharmacogenomic testing and outcome among
depressed patients in a tertiary care outpatient
psychiatric consultation practice
JR Rundell, M Harmandayan and JP Staab
The authors tested the hypothesis that pharmacogenomic genotype knowledge is associated with better clinical and cost
outcomes in depressed patients, after controlling for other factors that might differentiate tested and non-tested patients.
Medical records of 251 patients, seen in the Mayo Clinic Rochester outpatient psychiatric practice, who had patient health
questionnaire-9 (PHQ-9) scores before and after consultation, were reviewed. Comparisons of differences in pre-consultation
and post-consultation depression scores and slopes between tested and non-tested patients and between genotype categories
of tested patients, were evaluated, along with healthcare cost and utilization comparisons between tested and non-tested
patients, using Kruskal–Wallis tests, Wilcoxon rank-sum tests and group mean comparisons, controlling for signiﬁcant
univariate demographic and clinical differences. Tested patients had signiﬁcantly higher depression diagnosis frequency,
baseline PHQ-9 scores, family history of depression, psychiatric hospitalization history, and higher numbers of antidepressant,
mood stabilizer and antipsychotic medication trials. After controlling for these differences, there were no differences between
tested and non-tested patients in post-baseline depression scores or slopes for CYP genotype categories. For patients with
5-HTTLPR testing, therewas signiﬁcantly more depressionscore improvement for patients with the long/long genotype at time 4
(N¼55, v
2-value¼8.0492, P¼0.018) and at time 5 (N¼44, v
2-value¼6.1492, P¼0.046). For a subgroup (n¼46) with Xtwo
pre-andXtwopost-baselinePHQ-9scores,themeandifferencebetweenpre-baselineandpost-baseline PHQ-9scoreslopesfor
tested patients was  0.08 (median  0.01; range  1.20 to 0.15) compared with 0.13 (median 0.02; range  0.18 to 2.16) for non-
tested patients (P¼0.03). Among genotype categories, mean differences between pre-consultation and post-consultation
slopes were signiﬁcantly better for poor CYP2D6 metabolizers than intermediate or extensive metabolizers (P¼0.04); there was
a trend for slope differences to be better for 5-HTTLPR long/long genotype patients (P¼0.06). Subsets of local tested and
consultant-adjusted non-tested controls (n¼19), who had 8 years of longitudinal care within the health system, had similar
overallmeanhealthcarecostsbeforeandaftertesting;however,testedpatientsonaveragehadsigniﬁcantlyfewertime-adjusted
post-baseline psychiatric admissions (0.8 vs 3.8, P¼0.04) and fewer time-adjusted psychiatric consultations and
comprehensive mental health-specialty evaluations (4.2 vs 9.9, P¼0.03). Prospective study is indicated as to whether and
how pharmacogenomic testing in a psychiatric consultation practice may improve clinical and cost outcomes.
Translational Psychiatry (2011) 1, e6; doi:10.1038/tp.2011.7; published online 10 May 2011
Introduction
Pharmacogenomic testing might be most useful in psychiatric
patients who have treatment resistance, intolerable adverse
effects or the potential for problematic drug–drug or
drug–disease interactions.
1–9 Mayo Clinic, Rochester, MN,
USA has an outpatient consultative psychiatry practice that
collects a standard set of clinical data for each patient seen in
consultation, including a standard method for recording
historical psychotropic medication trials. Patients sometimes
receive pharmacogenomic tests as a part of their consultation
and results obtained are used in management recommenda-
tions.
5,6 This study sought to examine the hypotheses that
pharmacogenomic genotype knowledge is associated with
better clinical, cost and healthcare utilization outcomes, after
controlling for other clinical variables that might differentiate
tested and non-tested patients.
Patients and methods
Medical records of 2,390 patients seen in the Mayo Clinic
Rochester outpatient psychiatric consultation practice
between 1 January 2006 and 31 May 2010 were reviewed;
251 (10.5%) patients met the study’s inclusion criterion: a
patient health questionnaire (PHQ)-9 (10) scale score was
recorded (PHQ-9, 10) at the time of psychiatric consultation
and at least two PHQ-9 scores that followed psychiatric
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routinely in this practice, most patients present for a one-time
consultation or come to Mayo Clinic from other geographic
locations and are not followed longitudinally. Therefore, only
a minority of patients have longitudinal PHQ-9 scores.
A baseline PHQ-9 score was deﬁned asa measure of severity
of depression. For tested patients, the baseline PHQ-9 score
was the score that most closely preceded pharmacogenomic
testing; generally the date of the psychiatric consultation
during whichtesting wasordered. For non-testedpatients,the
baseline PHQ-9 was the score recorded on the date of their
baseline psychiatric consultation. Post-consultation PHQ-9
scores were required to be at least 14 days after the
consultation, that is, the minimum amount of time to reason-
ably expect to begin to see a clinical response if a medication
was initiated by the clinic. A total of 146 of the 251 patients
(58%) had taken at least one of the following pharmaco
genomictests—cytochromeP4502D6(CYP2D6),CYP2C19,
CYP2C9, serotonin transporter genotype (5-HTTLPR).
Comparisons of demographic and clinical features between
tested and non-tested patients were evaluated using Wilcox-
on rank-sum and w
2-tests. For the 251 study patients, PHQ-9
scores were grouped into those that occurred before or on the
baseline date and into those that occurred on or after 14 days
after the consultation date. A slope representing change in
PHQ-9 scores over time was calculated for the tested and
non-tested subgroups.
Out of the 251 study patients, 46 had at least two PHQ-9
scores that preceded the psychiatric consultation and at least
two PHQ-9 scores that followed the baseline psychiatric
consultation. Again 29 of these 46 patients (63%) had
pharmacogenomic testing. For these 46 patients, differences
in pre-baseline and post-baseline PHQ-9 slopes were
calculated. For each patient a slope representing the change
in pre-consultation PHQ-9 scores over time was calculated
using a linear regression model. This was subtracted from the
slope calculated using all post-consultation PHQ-9 scores.
Differences in slopes among genotype categories were
also evaluated. As the distribution of the differences in the
slopes for these analyses was not approximately normal, the
differences were ranked and then compared between tested
and non-tested patients using univariate and multivariable
linear regression models. Comparisons of differences in
depressionscoreslopeswereevaluatedusingKruskal–Wallis
and Wilcoxon rank-sum tests.
Healthcare utilization costs between January 2006 and
June 2010 were retrieved for 92 of the 251 study patients who
lived entirely within the local community during the study
period and received all of their local healthcare and mental
healthcare at Mayo Clinic Rochester. Differences in total
costs from pre-baseline to post-baseline were evaluated by
subtracting pre-baseline costs from post-baseline costs.
Overall, 45 (49%) had pharmacogenomic testing and 47
(51%) did not. Healthcare cost estimation (Olmsted County,
Minnesota Healthcare Expenditure and Utilization Database
maintained at Mayo Clinic). All healthcare costs were inﬂated
to the year 2010.
To examine mean numbers of medical and mental health
admissions, consultations and follow-up/treatment visits, the
time frame was expanded to the datesfrom January 2002 and
June 2010, covering the period of time when patient records
for local patients were consolidated into the Mayo Clinic
electronicmedicalrecord.Becauseapreviousstudyindicated
variability among consultants, in this clinic, in terms of
propensity, to order pharmacogenomic testing,
5 a subset of
tested and non-tested patients were identiﬁed who saw the
four consultants working in the clinic who most frequently
ordered pharmacogenomic testing. Nineteen local patients
hadtestingorderedbyoneofthesefourconsultants,andwere
compared with 19 non-tested patients whose baseline
psychiatric consultation was performed by the same
consultants in the same frequency proportion.
Cost data were compared between tested and non-tested
patientsusinglinearregressionmodels,bothunivariately,and
after adjusting for factors found in the univariate analysis to be
signiﬁcantly different between tested and non-tested patients.
As the distribution of costs was not approximately normal,
data were ranked before the modeling. Comparisons of costs
among genotypes for tested patients were evaluated using
Kruskal–Wallis and Wilcoxon rank-sum tests. As the distribu-
tion of the differences was not approximately normal, the
differences were ranked and then compared using univariate
and multivariable linear regression models. For healthcare
utilization data, tests of group means were assessed; the
numbers of clinical encounters were adjusted to take into
accountthe varying ratios of time elapsed betweenthe start of
the study period and the baseline testing or consultation, and
between the baseline testing or consultation and the end of
study period. As a previous study had demonstrated variation
in ordering patterns among consultants, a separate compar-
isonofgroupmeanswasconductedforasubgroupofpatients
with identical proportions of ordering consultant frequencies,
and only using the four consultants ordering testing most
frequently. In addition, the test of group differences for the
entire study sample was conducted a second time, adjusting
forordering consultant, asan additional methodto account for
this potential confounder of consultant variation in ordering
practices.
Statistical analyses were performed using the SAS soft-
ware package (SAS Institute, Cary, NC, USA). All tests were
two-sided and P-values o0.05 were considered statistically
signiﬁcant. This study was conducted in full compliance with
allpoliciesandproceduresoftheInstitutionalReviewBoardat
the Mayo Clinic. Study data were abstracted from medical
records of patients who gave informed consent for their charts
to be reviewed for research purposes.
Results
As this was an exploratory study, over 50 demographic and
clinical variables were assessed to determine whether there
were differences between tested and non-tested patients that
might account for group differences. Table 1 summarizes
univariate comparisons that were statistically signiﬁcant.
Major depressive disorder diagnosis frequency, baseline
PHQ-9 score, family history of mood disorder, psychiatric
hospitalization history and numbers of previous antidepres-
sant, mood stabilizer and antipsychotic trials, were signiﬁ-
cantly different, all higher in the tested group, indicating
greater degrees of psychiatric predisposition and depression
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Translational Psychiatryseverity. There were no statistically signiﬁcant demographic
differences between any groups compared in this study.
These factors became the basis of the logistic regression
analyses.
Post-day 14 serial depression severity scores. A total of
301 patients had CYP2D6 testing and initial PHQ-9 scores;
lesser numbers had CYP2C19 (N¼289), CYP2C9 (N¼166)
and 5HTTLPR (N¼205) testing and initial rating scale
scores. Subsets of those patients had serial depression
rating scale screening. Approximately one in six patients had
as many as ﬁve follow-up depression severity scores. There
were no signiﬁcant differences over time among CYP
genotype categories. For 5-HTTLPR categories, there was
signiﬁcantly greater improvement among long/long genotype
patients at time 4 (N¼55, mean duration of time from initial
testing 13.3 weeks, range 4.0–53.3 weeks, w
2-value 8.0492,
P¼0.018) and at time 5 (N¼44, mean duration of time from
initial testing 18.4 weeks, range 5.6–78.8 weeks, w
2-value
6.1492, P¼0.046) (Figure 1).
Post-day 14 depression severity rating scale slopes.
There were 120 patients with at least two post-day 14
depression severity rating scale scores (mean 7.9; median 4;
range 2–53), including 67 (56%) who underwent
pharmacogenomic testing and 53 (44%) who did not. The
mean slope representing the change in post-day 14 PHQ-9
scores, measured from baseline testing or consultation date,
over time, was  0.07 (median 0.00; range  1.47 to 0.17).
The mean slope for tested patients was  0.06 (median 0.00;
range  1.47 to 0.17) compared with  0.07 (median  0.01;
range  1.28 to 0.08) for non-tested patients (P¼0.96).
There were no statistically signiﬁcant differences in slopes
between tested and non-tested patients after adjusting for
diagnosis of major depressive disorder (P¼0.66), baseline
PHQ-9 score (P¼0.39), family history of mood disorder
(P¼0.96), numbers of previous antidepressant, mood
stabilizer and antipsychotic trials (P¼0.95), psychiatric
hospitalization history (P¼0.49) or after adjusting for all of
the features listed above (P¼0.88). There were no
signiﬁcant differences in post-consultation PHQ-9 slopes
among genotype categories (CYP2D6, CYP2C19, CYP2C9,
5-HTLLPR) for tested patients.
Differences in pre-baseline to post-baseline depression
severity scale score slopes. There were 46 patients with at
least two pre-baseline depression severity scale scores
Table 1 Comparisons of signiﬁcant differences between patients with and without pharmacogenomic testing, N¼251
Clinical feature Testing P-value
No (N¼105) Yes (N¼146)
Mean (median; range)
Baseline PHQ-9 scale score (N¼202) 10.8 (10; 0–27) 14.8 (15; 0–26) o0.001
Previous antidepressant trials (N¼224) 1.9 (1; 0–10) 4.6 (4; 0–15) o0.001
Previous mood stabilizer trials (N¼239) 0.2 (0; 0–3) 0.8 (0; 0–12) o0.001
Previous antipsychotic trials (N¼242) 0.4 (0; 0–6) 0.8 (0; 0–6) o0.001
N (%)
Major depressive disorder diagnosis 61 (58) 108 (74) 0.008
Family history of mood disorders 59 (56) 109 (75) 0.002
Psychiatric hospitalization history 0 (0) 43 (29) o0.001
Previous antidepressant trials
0 28 (27) 1 (1) o0.001
X1 77 (73) 145 (99)
Previous mood stabilizer trials
0 88 (84) 84 (58) o0.001
X1 17 (16) 62 (42)
Previous antipsychotic trials
0 88 (84) 82 (56) o0.001
X1 17 (16) 64 (44)
Abbreviation: PHQ, patient health questionnaire.
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Figure 1 PHQ-9 scores over time by HTT.
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Translational Psychiatry(mean 12.4; median 6.5; range 2–69) and at least two
post-baseline scores (mean 9.6; median 5; range 2–54),
including 29 (63%) who underwent pharmacogenomic testing
and 17 (37%) who did not. The mean difference for all 46
patients between the pre-baseline and post-baseline slopes
was 0.00 (median  0.01; range  1.20 to 2.16). The mean
difference for tested patients was  0.08 (median  0.01;
range  1.20 to 0.15) compared with 0.13 (median 0.02;
range  0.18 to 2.16) for non-tested patients (P¼0.03). The
signiﬁcant difference between tested and non-tested patients
remained after adjusting for diagnosis of major depressive
disorder (P¼0.028), family history of mood disorder
(P¼0.046) and numbers of previous antidepressant, mood
stabilizer and antipsychotic trials (P¼0.041), but not after
adjusting for baseline PHQ-9 score (P¼0.28), psychiatric
hospitalization history (P¼0.14) or after adjusting for all
of the features listed above (P¼0.42). Comparisons of
differences in pre-baseline to post-baseline depression
severity scale score slopes among genotypes for tested
patients are summarized in Table 2. There was a trend for
pre:post-baseline mean slope differences to be more
favorable for the long/long genotype category ( 0.30) than
short/long ( 0.02) and short/short ( 0.04) genotype
categories (P¼0.06).
Summary of healthcare costs and utilization. There was
no statistically signiﬁcant difference in post-day 14 mean
healthcare costs between 2006 and 2010 in tested and non-
tested patients after adjusting for family history of mood
disorder, diagnosis of major depressive disorder, baseline
depression severity rating scale score, history of psychiatric
admission, and numbers of previous antidepressant, mood
stabilizer and antipsychotic medication trials. There was lack
of group differences when the 26 patients with histories of
psychiatric admissions were analyzed separately and when
patients without histories of psychiatric admissions were
analyzed separately. When mean pre-baseline healthcare
costs are compared with post-baseline costs, there is a
nonsigniﬁcant trend for tested patients to have a higher mean
cost ($5,010, median  $2,167, range  $95051 to $157716)
than non-tested patients ( $6,693, median  $9,511, range
 $108290 to $210716; P¼0.08). The difference was
statistically signiﬁcant after adjusting for a diagnosis of
major depressive disorder (P¼0.049) and after adjusting
for numbers of previous antidepressant, mood stabilizer and
antipsychotic trials (P¼0.02), but not after adjusting for
baseline depression severity rating scale score (P¼0.34),
family history of mood disorder (P¼0.07), practice setting
(P¼0.46) or after adjusting for all of the features listed above
(P¼0.90). After removing patients without history of
psychiatric admission from the analysis, there were no
signiﬁcant differences between tested and non-tested
patients in terms of differences in pre-baseline and post-
baseline costs. There were also no signiﬁcant cost
differences among the subgroup of patients with psychiatric
admission histories.
When adjusted pre-baseline and post-baseline healthcare
utilization categories were compared between tested and
non-tested patients, several nonsigniﬁcant trends were
observed (Table 3). Tested patients, after baseline testing or
consultation, had a trend toward a higher mean number of
post-baseline medical-surgical outpatient specialty compre-
hensive evaluations or consultations (15.6 vs 17.7), but
relatively smaller than the increase observed (P¼0.09) in
non-tested patients (15.5 vs 31.3). Tested patients, after the
baseline testing or consultation, had a trend toward a higher
mean number of psychiatric admissions (0.8 vs 2.2),
but relatively smaller than the observed (P¼0.09) increase
in non-tested patients (0.2 vs 2.4). Tested patients, after the
baseline testing or consultation, had a trend toward a stable
andrelativelysmallermeannumberofsubsequentpsychiatric
consultations or mental health comprehensive specialty
evaluations (3.8 vs 3.9) compared with (P¼0.07) non-tested
patients (1.6 v 6.1). There were no signiﬁcant differences
between tested and non-tested patients in terms of mean
numbers of medical-surgical or mental health follow-up or
treatment visits. There were no group differences in mean
numbers of electroconvulsive therapy sessions. These trends
held (P40.05 and o0.10) after adjusting for ordering
consultant in the analysis, but did not become signiﬁcant.
For the subset of tested (n¼19) and non-testedconsultant-
adjusted (n¼19) patients, two signiﬁcant differences
emerged in terms of healthcare encounters (Table 3). Tested
patients, after the baseline testing or consultation, had
stable mean numbers of psychiatric admissions (1.0 vs 0.8),
relatively smaller (P¼0.04) than the increase in mean
numbers of psychiatric admissions seen among non-tested
patients (0.1 vs 3.8). Tested patients, after the baseline
testing or consultation, had fewer mean numbers of psychia-
tric consultations or comprehensive mental health specialty
evaluations (5.0 vs 4.2), in contrast (P¼0.03) to the higher
mean numbers of related encounters observed in non-tested
patients (1.5 vs 9.9). There were no signiﬁcant group
differences in mean numbers of medical-surgical clinical
encounters of any category or mean numbers of mental
health specialty follow-up visits. There were no group
differences in mean number of electroconvulsive therapy
sessions.
Table 2 Comparisons of differences in pre-baseline to post-baseline PHQ
slopes among cytochrome P450 genotypes
Genotype Difference in slopes P-value
Mean (median; range)
2D6
Poor, N¼5  0.17 ( 0.05;  0.63 to 0.00) 0.04
Intermediate, N¼13  0.08 ( 0.01;  1.20 to 0.15)
Extensive, N¼7  0.05 ( 0.04;  0.12 to  0.01)
2C19
Poor/intermediate, N¼5  0.03 ( 0.02;  0.14 to 0.15) 0.67
Extensive, N¼24  0.09 ( 0.01;  1.20 to 0.08)
2C9
Intermediate, N¼5  0.04 ( 0.04;  0.14 to 0.02) 0.31
Extensive, N¼5 0.02 ( 0.01;  0.05 to 0.08)
HTT
L/L, N¼6  0.30 ( 0.04;  1.20 to 0.06) 0.06
S/L, N¼13  0.02 ( 0.01;  0.12 to 0.15)
S/S, N¼5  0.04 ( 0.01;  0.10 to  0.01)
Abbreviation: PHQ, patient health questionnaire.
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Tested patients differed from non-tested patients across a
number of clinical domains, including higher likelihood of
major depressive disorder diagnosis (in relative comparison
with anxiety, other mood and other psychiatric disorders),
higher numbers of psychotropic medication trials considered
to be adequate in terms of duration and dosage, greater mood
disorderpredispositionasmeasuredbyfamilyhistoryofmood
disorder, psychiatric hospitalization history and greater
severity of baseline depression as measured by PHQ-9 score
(Table 1). These data suggest that consulting psychiatrists at
this tertiary care referral center are more likely to order
pharmacogenomic tests when patients are more severely
depressed, report predisposition for mood disorder, or report
treatment non-response or poor tolerability. The average
tested patient had 4.6 antidepressant medication trials before
pharmacogenomic testing; the correct number of medication
trials that may trigger pharmacogenomic testing in future
clinical algorithms will depend on prospective data that
assesses the affect of pharmacogenomic testing on clinical
outcomes and on cost-effectiveness.
Though underpowered to detect a signal for some of the
variables of ultimate interest, this retrospective study presents
preliminary evidence that there maybe a potential clinical impact
of ordering pharmacogenomic testing as measured by more
favorable post-testing depression severity rating scale score
slopes when compared with pre-testing slopes. The difference
holds up during comparisons of other group differences, except
when controlling for baseline P H Q - 9s c o r ea n dp s y c h i a t r i c
hospitalization history, suggesting that at least part of the
difference in rating scale score slopes maybe accounted for by
tested patients being more severely ill and having a larger
potential distance for scores to fall relative to non-tested patients.
Healthcare cost and healthcare utilization analyses did not
ﬁnd a signiﬁcant impact of pharmacogenomic testing on costs
in this health system. A conservative approach to detecting a
cost impact was used, which may have made it difﬁcult to
discern an impact, if present, because 4 years of clinical costs
were evaluated. It may be difﬁcult to detect the impact of a
single event such as a laboratory test over such a long period
of time. Inaddition, there may be affects oncosts not detected
by the methodology used. For example, pharmacogenomic
testing may have increased some costs (for example,
laboratory and outpatient psychotherapy costs) and de-
creased others (for example, costs related to decreased
admissions).
There is evidence from this data of a potential impact of
testing in terms of decreased numbers of clinical encounters
insomecategories,whenotherpotentiallycontributoryclinical
variables and ordering consultant are adjusted for, though
coststhemselveswerenotappreciablyaffected.Thiscouldbe
related to variability of costs related to services (for example, an
inpatientadmissionbeingmanytimesmoreexpensivethanother
categories of services studied). These ﬁndings are preliminary
and should be replicated or used to generate hypotheses and
estimates of necessary power for prospective studies.
At a translational level, treatment plans for patients who
have unfavorable genotypes (that is, poor CYP2D6 metabo-
lizers, presence of a short 5-HTTLPR allele) may include
selecting a medication that is predominantly a substrate of a
different CYP isoenzyme and having a lower threshold for
Table 3 Adjusted mean medical-surgical and mental health admissions and outpatient encounters following pharmacogenomic testing or psychiatric consultation
without pharmacogenomic testing (adjusted for ratio of time between beginning of study period and baseline testing or consultation, and between baseline testing or
consultation and end of study period)
Clinical encounter category Local
tested
patient
utilization
(n¼45)
Local
non-
tested
patient
utilization
(n¼47)
F ratio/
Probability4F
Local tested
consultant
control
patient
utilization
(n¼19)
Local
non-
tested
consultant
control
patient
utilization
(n¼19)
F ratio/
Probability4F
Pre-baseline medical-surgical admissions 0.6 0.9 0.2852/0.5968 0.7 1.0 0.2088/0.6488
Post-baseline medical-surgical admissions 1.9 3.6 3.4 6.1
Pre-baseline medical-surgical consultations/specialty
evaluations
15.6 15.5 2.9681/0.0940 21.2 15.6 0.4782/0.4910
Post-baseline medical-surgical consultations/specialty
evaluations
17.7 31.3 12.0 37.4
Pre-baseline medical-surgical follow-up/treatment visits 75.3 75.6 1.5021/0.2288 84.8 80.7 0.0155/0.9148
Post-baseline medical-surgical follow-up/treatment visits 52.9 126.7 56.9 151.5
Pre-baseline mental health admissions 0.8 0.2 3.0303/0.0908 1.0 0.1 4.4145/0.0385
Post-baseline mental health admissions 2.2 2.4 0.8 3.8
Pre-baseline mental health consultations/specialty
evaluations
3.8 1.6 3.5185/0.0693 5.0 1.5 5.0197/0.0275
Post-baseline mental health consultations/specialty
evaluations
3.9 6.1 4.2 9.9
Pre-baseline mental health follow-up/treatment visits 43.4 18.0 1.1153/0.2984 41.9 15.8 1.8423/0.1781
Post-baseline mental health follow-up/treatment visits 58.2 56.4 59.3 66.7
Pre-baseline ECT sessions 2.5 0.3 1.1529/0.2905 5.4 0.2 2.3644/0.1277
Post-baseline ECT sessions 8.3 2.9 28.7 5.8
Abbreviation: ECT, electroconvulsive therapy.
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Translational Psychiatrypharmacological augmentation strategies. Evidence-based
non-pharmacological interventions such as cognitive behavi-
oral therapy and behavioral activation maybe used more
frequently or earlier in the course of treatment.
6 The ﬁndings
from this study, including possible associations between
5-HTTLPR allele category and treatment response, are
consistent with ﬁndings from other studies.
3,5,7,9,10 On the
basis of these potential associations, well-powered prospec-
tive studies and other study paradigms are needed to further
inform the clinical utility and cost-effectiveness of these tests
in the setting of depression and other psychiatric disorders in
the medically ill patients.
These results are limited by the small sample size and
retrospective nature of the study. It was underpowered to fully
address the aims of the study across all variables that could
potentially account for group differences. The 251 patients
who met data analysis inclusion criteria only represent 11% of
the 2,390 patients seen in consultation in this clinic, and may
not be representative of all clinic patients. For example, 58%
of patients who met study inclusion criteria had pharmaco
genomic testing; for the overall clinic population, the
frequency is 17%. No algorithm or testing parameters were
available to guide ordering practice, hence, psychiatric
consultants varied in their ordering thresholds and prac-
tices.
11 Data regarding the number and adequacy of medica-
tion trials were dependent on patient memory when previous
records were not available, therefore, it was not possible to
conﬁrm with accuracy whether genotype categories of tested
patients were managed before testing with adequate dosage
levels or durations of treatment with medications.
This retrospective study was an exploratory investigation.
Therefore, a large number of measures were screened in the
univariate analysis without correcting for multiple compar-
isons. This step was undertaken to improve statistical power
for logistical regression, therefore, any results from the
univariate analysis should be considered preliminary. Logistic
regression is less prone to type 1 errors when adequately
powered, and the high number of variables carries a risk for
false positive results.
12
Conclusion. Pharmacogenomic testing has the potential to
contribute to individualizing outpatient psychiatric practice
by helping identify patients prone to treatment resistance or
non-tolerance due to genetic factors. Prospective study is
important to deﬁne under what, if any, speciﬁc circumstances
pharmacogenomic tools help customize and optimize
cost-effective treatment recommendations for each
patient’s unique genetic and environmental factors.
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